1. Otsuka M and Koike K. Should level of HBV-RNA be used to determine when patients should stop treatment with nucleos(t)ide analogues. Clin Gastroenterol Hepatol. 2020;18(3):551-552.
2. Sekiba K, Otsuka M, Koike K. Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System. J Vis Exp. 2019 Dec 21;(154).
3. Sekiba K, Otsuka M, Ohno M, Yamagami M, Kishikawa T, Seimiya T, Suzuki T, Tanaka E, Ishibashi R, Funato K, and Koike K. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, is a potent inhibitor of hepatitis B virus. Hepatology 2019 May;69(5):1903-1915.
4. Yorozu A, Yamamoto E, Niinuma T, Tsuyada A, Maruyama R, Kitajima H, Numata Y,Kai M, Sudo G, Kubo T, Nishidate T, Okita K, Takemasa I, Nakase H, Sugai T, Takano K, Suzuki H. Upregulation of AEBP1 in endothelial cells promotes tumor angiogenesis in colorectal cancer. Cancer science. 2020, 10.1111/cas.14360
5. Fujita R, Yamamoto T, Arimura Y, Fujiwara S, Tachiwana H, Ichikawa Y, Sakata Y, Yang L, Maruyama R, Hamada M, Nakao M, Saitoh N, Kurumizaka H. Nucleosome destabilization by nuclear non-coding RNAs.Communications biology. 2020, 3(1) 60-6010.1038/s42003-020-0784-9
6. Ohka F, Shinjo K, Deguchi S, Matsui Y, Okuno Y, Katsushima K, Suzuki M, Kato A, Ogiso N, Yamamichi A, Aoki K, Suzuki H, Sato S, Rayan NA, Prabhakar S, Goeke J, Shimamura T, Maruyama R, Takahashi S, Suzumura A, Kimura H, Wakabayashi T, Zong H, Natsume A, Kondo Y. Pathogenic Epigenetic Consequences of Genetic Alterations in IDH-Wild-Type Diffuse Astrocytic Gliomas. Cancer research. 2019, 79(19) 4814-482710.1158/0008-5472.CAN-19-1272
7. Niinuma T, Kitajima H, Kai M, Yamamoto E, Yorozu A, Ishiguro K, Sasaki H, Sudo G, Toyota M, Hatahira T, Maruyama R, Tokino T, Nakase H, Sugai T, Suzuki H. UHRF1 depletion and HDAC inhibition reactivate epigenetically silenced genes in colorectal cancer cells. Clinical epigenetics. 2019, 11(1) 7010.1186/s13148-019-0668-3